Cargando…
Human pancreatic cancer patients with Epithelial-to-Mesenchymal Transition and an aggressive phenotype show a disturbed balance in Protein Phosphatase Type 2A expression and functionality
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) has a low survival, its incidence is rising and little therapeutic improvements are expected in the near future. It has been observed that Epithelial-to-Mesenchymal transition (EMT) contributes (including in PDAC) to a more aggressive cancer phenot...
Autores principales: | van Pelt, Jos, Meeusen, Bob, Derua, Rita, Guffens, Liesbeth, Van Cutsem, Eric, Janssens, Veerle, Verslype, Chris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176933/ https://www.ncbi.nlm.nih.gov/pubmed/37170215 http://dx.doi.org/10.1186/s12967-023-04145-z |
Ejemplares similares
-
PME-1 sensitizes glioblastoma cells to oxidative stress-induced cell death by attenuating PP2A-B55α-mediated inactivation of MAPKAPK2-RIPK1 signaling
por: Guffens, Liesbeth, et al.
Publicado: (2023) -
PME-1-regulated neural cell death: new therapeutic opportunities?
por: Guffens, Liesbeth, et al.
Publicado: (2023) -
Acriflavine Inhibits Acquired Drug Resistance by Blocking the Epithelial-to-Mesenchymal Transition and the Unfolded Protein Response
por: Dekervel, Jeroen, et al.
Publicado: (2016) -
In vivo pieces of the PP2A onco-puzzle fallen into place
por: Meeusen, Bob, et al.
Publicado: (2017) -
Anti-Cancer Activity of Acriflavine as Metabolic Inhibitor of OXPHOS in Pancreas Cancer Xenografts
por: Bulle, Ashenafi, et al.
Publicado: (2020)